儿童大肠埃希菌尿路感染112例临床治疗分析

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1281 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To summarize the curative effects of the antibiotics used for the treatment of the urinary tract infection (UTIs) in children caused by Escherichia coli and to provide the basis for empirical therapy. To discuss the associated risk factors of UTIs caused by Extended-Spectrum β-Lactamase (ESBLs)-producing Escherichia coli which was no response to the cephalosporin antibiotics therapy. Methods: The treatment outcomes of 112 UTIs caused by Escherichia coli from 2011, January to 2012, December in our hospital were analyzed. Results: Effective power was 100%, if according to antibiotic susceptibility testing. The curative effect of empiric therapy for non-ESBL UTIs was also perfect. However, the curative effect of empiric therapy for ESBL UTIs was suboptimal, cephalosporin antibiotics was only 63.27%, β-Lactamase inhibitors combined drugs or carbopenems were nearly 100% for ESBL UTIs patients. In the subgroup of empiric therapy for ESBL UTIs with cephalosporin antibiotics, the no-response group had higher level of C-reactive protein, white blood count, higher rate of urinary tract anomalies, microalbumin and β2-microglobulin, when compared with response group. Conclusion: Empiric therapy by the third generation cephalosporin should be cautious for the patients with urinary tract anomalies, high level of inflammatory markers, microalbumin or β2-microglobulin, while β-Lactamase inhibitors combined drugs could be optional. However, in refractory and severe cases, carbopenems antibiotics are recommended.

Key words： urinary tract infection escherichia coli therapy children

Received: 11 September 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YU Lingfang
	CHEN Minguang
	YANG Qing
	ZHUANG Jieqiu.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2015/V45/I7/534

[1] 胡亚美, 江载芳. 诸福棠实用儿科学(下册)[M]. 7版. 北京:人民卫生出版社, 2005: 1667-1671.
[2] Downs SM. Technical report: urinary tract infections in febrile infants and young children. The Urinary Tract Subcommittee of the American Academy of Pediatrics Committee on
Quality Improvement[J]. Pediatrics, 1999, 103(4): e54.
[3] Saadeh SA, Mattoo TK. Managing urinary tract infections [J]. Pediatr Nephrol, 2011, 26(11): 1967-1976.
[4] 胡斌飞, 张琦, 李白恩. 175例小儿尿路感染的病原菌分布及药敏结果分析[J]. 现代实用医学, 2011, 23(7): 814-816.
[5] 余灵芳, 杨青, 王德选, 等. 小儿尿路感染病原菌8年变迁及耐药分析[J]. 中国实用儿科杂志, 2013, 28(9): 707-710.
[6] 高秀芝, 张丽琼, 陈丽娟. 婴幼儿尿路感染常见病原菌及药敏分析[J]. 国际检验医学杂志, 2009, 30(3): 289-290.
[7] 杨茜, 王墨. 365例尿路感染住院患儿临床及感染菌耐药性分析[J]. 儿科药学杂志, 2011, 17(3): 36-41.
[8] 刘延霞, 林瑞霞, 杨青. 小儿尿路感染致病菌分布及药敏分析[J]. 温州医学院学报, 2007, 37(6): 575-577.
[9] 余灵芳, 陈敏广, 杨青, 等. 产超广谱β-内酰胺酶大肠埃希菌儿童尿路感染临床特点及预测因素分析[J]. 浙江医学,2014, 36(20): 1687-1690.
[10] Whiting P, Westwood M, Bojke L, et al. Clinical effectiveness and cost-effectiveness of tests for the diagnosis and investigation of urinary tract infection in children: a systematic review and economic model[J]. Health Technol Assess, 2006, 10(36): 1-154.
[11] Pecile P, Romanello C. Procalcitonin and pyelonephritis in children[J]. Curr Opin Infect Dis, 2007, 20(1): 83-87.
[12] 张满生, 杨爱华, 张小云, 等. 尿α1-微球蛋白检测在尿路感染定位诊断中的意义[J]. 中国中西医结合肾病杂志, 2012, 13(9): 830-831.
[13] Lichtenberger P, Hooton TM. Complicated urinary tract infections[J]. Curr Infect Dis Rep, 2008, 10(6): 499-504.
[14] 胡红兵, 夏维. 儿童尿路感染常见病原菌的分布及耐药性[J]. 中华医院感染学杂志, 2011, 21(6): 1263-1264.
[15] El-Gamal MI, Oh CH. Current status of carbapenem antibiotics[J]. Curr Top Med Chem, 2010, 10(18): 1882-1897.
[16] 谢泉琨, 刘书真. 头孢美唑治疗急性尿路感染的疗效观察[J]. 中国药房, 2011, 22(28): 2644-2646.